Tvardi Therapeutics is trading at $1.86 (+6.81%) in pre-market, but the catalyst is unclear.
- No clear company-specific announcement dated September 2, 2026 was identified; the latest investor-relations update concerned participation in September healthcare conferences.
- S&P 500 and Nasdaq futures are modestly lower amid geopolitical, oil, and rate concerns, offering no direct explanation.
- The move may reflect speculative activity or a delayed reaction to earlier TTI-109 clinical news.